A New Era for oHCM Patients: The Landmark Myqorzo FDA Approval
Introduction: A Landmark Decision for Cardiovascular Health The landscape of cardiovascular medicine has been fundamentally reshaped by a recent, pivotal announcement: the Myqorzo FDA approval . This decision by the U.S. Food and Drug Administration (FDA) grants market access to Myqorzo (aficamten), a novel cardiac myosin inhibitor developed by Cytokinetics, for the treatment of adults …